Table 1.
Patient characteristics at diagnosis and at recurrence for the whole cohort
| At diagnosis | |
|---|---|
| Age | 61 ± 10 |
| Male | 32 (54) |
| Surgical procedure | |
| Stereotactic biopsy | 20 (34) |
| Subtotal resection | 28 (47) |
| Complete resection | 11 (19) |
| Adjuvant systemic therapy | |
| Temozolomide | 52 (88) |
| Bevacizumab | 1 (2) |
| Nivolumab | 1 (2) |
| Temozolomide with bevacizumab | 4 (6) |
| Temozolomide with nivolumab | 1 (2) |
| At recurrence | |
|---|---|
| Number of previous recurrences | |
| 0 | 45 (76) |
| 1 | 10 (17) |
| 2 | 3 (5) |
| 3 | 1 (2) |
| KPS | |
| 60 | 1 (2) |
| 70 | 10 (17) |
| 80 | 9 (15) |
| 90 | 35 (59) |
| 100 | 4 (7) |
| ADL | |
| 6 | 53 (90) |
| 5 | 2 (3) |
| 4 | 1 (2) |
| 3 | 2 (3) |
| 2 | 1 (2) |
| Multifocality | |
| Yes | 5 (8) |
| No | 54 (92) |
| Steroids | |
| Yes | 14 (24) |
| No | 45 (76) |
| Antiepileptic medication | |
| Yes | 35 (59) |
| No | 24 (41) |
| Headaches | |
| Yes | 14 (25) |
| No | 45 (75) |
| Motor deficiency | |
| Yes | 9 (85) |
| No | 50 (15) |
| Intracranial hypertension | |
| Yes | 0 (0) |
| No | 59 (100) |
| Adjuvant systemic treatment after reirradiation | 31(52) |
| Temozolomide | 12 (20) |
| Bevacizumab | 5 (8) |
| Fotemustine | 4 (7) |
| Temozolomide with bevacizumab | 3 (5) |
| Fotemustine with bevacizumab | 4 (7) |
| Lomustine with bevacizumab | 2 (3) |
| Nivolumab | 1 (2) |
Result: mean ± standard deviation or frequency (percentage)
RTCT, concomitant adjuvant chemotherapy plus radiotherapy; KPS, Karnofsky performance status; ADL, activity of daily living